Annual report pursuant to Section 13 and 15(d)

SETTLEMENT LIABILITY (Details Narrative)

v3.23.1
SETTLEMENT LIABILITY (Details Narrative) - USD ($)
 1 Months Ended 12 Months Ended
Nov. 12, 2021
Apr. 17, 2020
Apr. 02, 2020
Nov. 04, 2018
Nov. 30, 2020
Dec. 31, 2022
Dec. 31, 2021
Nov. 04, 2019
Loss Contingencies [Line Items]                
Royalty fees           $ 450,000  
Current portion of payable to licensor           4,599,000  
Royalties payments     $ 8,000,000 $ 20,000,000        
License to be paid   $ 8,000,000            
Interest payable               $ 1,000,000
Debt instrument, maturity date     Nov. 04, 2020          
License termination date   May 02, 2020            
Gain on settlement with licensor           6,743,000  
Restricted Cash           $ 338,000 5,891,000  
Amended Agreement [Member]                
Loss Contingencies [Line Items]                
License to be paid               3,000,000
Amended Agreement [Member] | April 1, 2020 [Member]                
Loss Contingencies [Line Items]                
License to be paid               8,000,000
Settlement Agreement [Member]                
Loss Contingencies [Line Items]                
Gain on settlement with licensor             $ 6,700,000  
REGENXBIO [Member]                
Loss Contingencies [Line Items]                
License to be paid               $ 10,000,000
Settlement liabilities, current $ 30.0              
Loss contingency settlement agreement terms (1) $20.0 million paid in November 2021 after execution of the Settlement Agreement, (2) $5.0 million on the first anniversary of the effective date of the Settlement Agreement, and (3) $5.0 million upon the earlier of (i) the third anniversary of the effective date of the Settlement Agreement or (ii) the closing of a Strategic Transaction, as defined in the Settlement Agreement. Under the Settlement Agreement’s terms, the prior license agreement between the parties is not reinstituted, and any future license agreement would need to be negotiated separately and require consideration in addition to the consideration set forth in the Settlement Agreement              
Interest rate stated percentage           9.60% 9.60%  
Restricted Cash             $ 5,000,000.0  
REGENXBIO [Member] | Due In November 2022 [Member]                
Loss Contingencies [Line Items]                
Debt instrument maturity date           November 2022 November 2022  
Long term debt           $ 4,600,000  
REGENXBIO [Member] | Due In November 2024 [Member]                
Loss Contingencies [Line Items]                
Debt instrument maturity date           November 2024 November 2024  
Long term debt           $ 4,200,000 $ 3,800,000  
Licensing Agreements [Member] | REGENXBIO [Member]                
Loss Contingencies [Line Items]                
Royalty fees       180,000,000        
Annual fees       20,000,000        
Payment for execution of contracts       10,000,000        
Current portion of payable to licensor       10,000,000        
Royalties payments       $ 60,000,000 $ 20,000,000      
Finite-lived intangible asset, useful life       8 years        
Loss contingency accrual       $ 8,000,000        
Payments for legal settlements       20,000,000        
Licensing Agreements [Member] | REGENXBIO [Member] | Maximum [Member]                
Loss Contingencies [Line Items]                
Annual fees       $ 100,000,000